☰
Innovent Biologics Inc., in collaboration with American pharmaceutical giant Eli Lilly and Company, have reportedly announced that the biomarker results of ORIENT-11 trials which were displayed during a mini verbal presentation at ESMO (European Society for Medical Oncology) Virtual Congress 2020.
As per the credible sources, ORIENT-11 is a phase 3 clinical trial that evaluates TYVYT® combined with ALIMTA® and platinum chemotherapy as a cure for recurrent or advanced nonsquamous non-small cell lung cancer without modifying ALK rearrangements or EGFR mutations.
In fact, the NMPA (National Medical Products Administration) of China has already approved the supplemental New Drug Application (sNDA) for this indication.
If sources are to be believed, data analysis on biomarker showed that MHC-II antigen presentation pathway has played a major role in immunotherapy-chemotherapy combination. Additionally, higher gene expression of this route can serve as a predictive biomarker which allows individuals to choose for whom this regimen can be beneficial.
Head of Department of Internal Medicine at Sun Yat-sen University Cancer Center as well as the primary investigator of the ORIENT-11 trials, Professor Li ZHANG, reportedly stated that there is improvement in efficiency when Sintilimab is combined with pemetrexed and platinum chemotherapy. He further added that there are no newly detected safety signals in nonsquamous metastatic or locally advanced NSCLC.
Dr. Li Wang, Senior VP at Lilly China as well as the Head of Lilly China Drug Development and Medical Affairs Center, claimed that exploring the use of biomarkers helps in effectively understanding cancer immunotherapy. She further mentioned that the company is thrilled about the results and is looking forward to presenting the results at ESMO.
Reportedly, the primary results on the research were declared in IASLC World Conference on Lung Cancer (WCLC) 2020 Virtual Presidential Symposium in a presentation held verbally and were published by Journal of Thoracic Oncology.
Source credits-
An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...
Swiftly Systems has reportedly achieved unicorn status, securing in funding through a Series C round. The prominent BRV Capital Management led this funding initiative. According to the earlier reports, Swiftly was adopted by hundreds of consumer b...
As per the reports, twelve nations with rainforests united to establish a collective initiative aiming to address climate change and safeguard biodiversity at summit held in Brazil. The declaration, titled "United for Our Forests," emerged ...
Meta Platforms has recently introduced Llama 2, an artificial intelligence large language model, for commercial use in collaboration with major cloud providers like Microsoft. Instead of charging for access or usage, Meta aims to share the model with...
Moderna Inc, a leading vaccine manufacturer, reportedly announced on Wednesday that it has entered into a memorandum of understanding (MoU) and a land collaboration agreement aimed at exploring opportunities for researching, developing, and producing...
The American footwear design & manufacturing company, Nike and Epic Games, the creators of the popular online game Fortnite, have joined forces in an exciting new collaboration. The partnership aims to bring about a groundbreaking change in the d...
© 2024 aeresearch.net. All Rights Reserved.